Customer No. 28880

CENTRAL FAX CENTER

Confirmation No. 1072

AUG 0 1 2005 PTO/SB/21 (09-04) Approved for use through 07/31/2005, OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Pappryork Reduction Act of 1995, no persons are required to respond lection of information unless it displays a valid OMB control number. **Application Number** 10/770,894 TRANSMITTAL Filing Date February 3, 2004 First Named Inventor **FORM** William W. McWhorter, Jr. Art Unit 1624 **Examiner Name** Kahsay Habte (to be used for all correspondence after initial filing) Attorney Docket Number Pharmacia 00560, Div.1 (PC27010) Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences Appeal Communication to TC ✓ Petition Amendment/Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer **Extension of Time Request** below); Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Authorization to charge the fee and any additional fees as necessary or credit any Reply to Missing Parts/ overpayment to deposit account 23-0455 is hereby given. Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Pharmacia & Upjohn Company Signature Printed name Suzanne M. Harvey Date Reg. No. ugust / -2005 42,640 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Doudre Cerene A. Boudrie Date Typed or printed name 14U8F

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the CNef Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

USPTO Fax No.

571-273-8300

Aug-01-2005 05:51pm FromPATENT PFIZER ANN ARBOR MI

7346222928

T-450 P.002

F-911

Confirmation No. 1072

RECEIVED **CENTRAL FAX CENTER**

"Official"

AUG 0 1 2005

Pharmacia 00560.Div 1 (PC 27010)

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT: William W. McWhorter, Jr.

EXAMINER: Kahsay Habte

SERIAL NO. : 10/770,894

ART UNIT

: 1624

FILED

: February 3, 2004

PAPER NO. :

FOR

: THERAPEUTIC 5-HT LIGAND COMPOUNDS

RESPONSE UNDER 37 CFR § 1.111(a)

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Office Action dated June 1, 2005, the Applicants respectfully request reconsideration of the above-identified application in view of the following remarks.

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks begin on page 9 of this paper.